US Patent

US8580781 — Pyridazinone derivatives

Composition of Matter · Assigned to Merck Patent GmbH · Expires 2030-03-19 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects pyridazinone derivatives that inhibit tyrosine kinases, particularly Met kinase, and can be used to treat tumors.

USPTO Abstract

Compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 4′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.

Drugs covered by this patent

Patent Metadata

Patent number
US8580781
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-03-19
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.